GlassScriptPhysician profile
Rabindra Girdhar
NPI 1245236405
$2,531.86
in general payments reported to CMS, 2019-2025
17 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $205 · 2021: $505 · 2022: $675 · 2023: $402 · 2024: $88.60 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $697.96 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $420.19 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $301.27 | 2022-2023 | Optimizer |
| Amgen INC. | $198.07 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.80 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $159.88 | 2022-2025 | Camzyos |
| Amarin Pharma, INC. | $112.56 | 2019-2020 | |
| Boston Scientific Corporation | $102.40 | 2019 | |
| Cvrx, INC. | $93.35 | 2022-2024 | Barostim Neo System |
| Pfizer INC. | $60.82 | 2019-2025 | |
| Novo Nordisk INC | $44.91 | 2023 | Ozempic, Rybelsus |
| Heartflow, INC. | $35.81 | 2023 | Ffrct |
| Kiniksa Pharmaceuticals, LTD. | $26.95 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.79 | 2022-2023 | Lifevest |
| Kestra Medical Technology Services, INC. | $25.51 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25.34 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabindra Girdhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.